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OBJECTIVES The purpose of this study was to assess whether the newer stent delivery systems provide a
stented lumen cross-sectional area (CSA) that is equal to the delivery balloon nominal
dimensions.
BACKGROUND First generation stents were often not adequately expanded with their delivery system and
frequently required higher pressure or a larger balloon after deployment. Newer stents were
designed to optimize expansion with noncompliant, high-pressure balloons provided as the
delivery systems.
METHODS Intravascular ultrasound (IVUS) was used to evaluate 38 stents in 32 patients after
deployment at 14 to 16 atm with their delivery balloon system. Minimum stent lumen CSA
and stent minimum lumen diameter (MLD) were measured by IVUS imaging. The
manufacturer’s expected stent diameter was defined as the balloon diameter measured by the
company at the maximum pressure used. The manufacturer’s expected stent area was
calculated based on the manufacturer’s expected stent diameter.
RESULTS The MLD (2.5  0.5 mm) and minimum stent CSA (6.0  1.7 mm2) by IVUS were
significantly smaller than the manufacturer’s expected stent diameter (3.5 0.4 mm) and area
(9.5  1.9 mm2) (p  0.0001, respectively). The mean MLD by IVUS was 72  8% of the
expected stent diameter, and the mean minimum stent CSA by IVUS was 62  10% of the
expected stent area.
CONCLUSIONS Despite moderately high-pressure inflations, the mean minimum stent CSA actually achieved
was, on average, only 62% of the manufacturer’s expected stent area. To optimize stent
deployment, these IVUS observations should be considered during coronary artery stenting.
(J Am Coll Cardiol 2001;38:1622–7) © 2001 by the American College of Cardiology
Compared with balloon dilation alone, the placement of a
coronary stent improves the immediate results as well as the
restenosis rate (1,2). Despite these benefits, in-stent resten-
osis remains a problem in interventional cardiology (3).
Stent deployment guided by intravascular ultrasound
(IVUS) may reduce the rate of restenosis by optimizing
stent expansion (4–7). The initial observations with IVUS
showed that first generation stents were not adequately
expanded and often required higher pressure or a larger
balloon after deployment (8–10). Other authors have sug-
gested that using high-pressure balloon inflation to maxi-
mize stent expansion may exacerbate vessel damage and
result in increased stent restenosis (11). It has been assumed
that the newer generations of stent delivery systems have
incorporated this information and, for any given pressure,
provide a stented lumen cross-sectional area (CSA) equal to
the manufacturer’s stated size. The purpose of this study was
to assess whether the manufacturer’s stated size could be
achieved by two of the newer stent delivery systems using
moderately high pressures for deployment.
METHODS
Study population. The study population consisted of 32
patients who had Tristar (Guidant Corporation, Temecula,
California) or S670 (Medtronic USA Inc., Minneapolis,
Minnesota) stents deployed at 14 to 16 atm with their
delivery balloon system between August 1999 and October
2000. In addition, patients had to have an IVUS evaluation
after stent deployment to be included in this retrospective
analysis.
Coronary angiography and stent deployment. Coronary
angiography was performed in a routine manner from the
femoral artery with a 6F or 8F catheter. Direct stenting was
used in eight lesions. Preparation for the stent was per-
formed on 30 lesions with conventional balloon angioplasty
alone in 12 cases, one with directional coronary atherec-
tomy, six with rotational coronary atherectomy and eight
with cutting balloon angioplasty. In addition, four lesions
were treated with an experimental thrombectomy device
before stenting (X-SIZER, Endicor Inc., San Clemente,
California). Guidant Tristar and AVE/Medtronic S670
stents were deployed at 14 or 16 atm with their delivery
balloon system. No patient had additional dilation after
stent insertion with another balloon catheter before the
IVUS examination.
IVUS. After stent deployment, the IVUS study was per-
formed with a 3.2F monorail system using a 30 MHz
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transducer-tipped catheter (Ultracross, CVIS/SCIMED
Inc, Sunnyvale, California). The IVUS imaging catheter
was passed over the guide wire at least 10 mm distal to the
stent. The IVUS imaging was performed during motorized
pullback (0.5 mm/s) of the catheter. The IVUS images were
recorded on S-VHS videotapes for subsequent review and
quantitative analysis.
Quantitative coronary angiography (QCA) measure-
ments. Quantitative coronary angiography measurements
were performed with an automated computer-based system
(CRS-PC, General Electric Company, Fairfield, Con-
necticut) by an experienced angiographer. The external
diameter of the contrast-filled catheter was used as the
calibration standard. Before and after stenting, lesion min-
imum lumen diameter (MLD) or stent MLD, lesion length
and reference diameter were measured. The percent diam-
eter stenosis was calculated automatically as the reference
lumen diameter  the MLD divided by the reference
diameter. Lesions were characterized according to the mod-
ified American College of Cardiology-American Heart
Association classification (12). The maximum balloon di-
ameter during stent deployment was measured and com-
pared with the manufacturer’s expected values and with the
stent lumen diameter measured by QCA.
IVUS measurements. The IVUS images were digitized
with a Macintosh G4 computer (Apple Corp., Cupertino,
California). Measurements were made with the use of
computerized planimetry with public-domain software
(NIH image). The digitized IVUS images were reviewed,
and the image slice with the minimum stent lumen CSA
was chosen for analysis. The minimum stent lumen CSA
and stent MLD were measured.
In addition, in 14 lesions from 11 patients, measurements
of stent lumen CSA were made every 1-mm along the
length of the stent from the distal to the proximal edge of
the stent. The minimum stent lumen CSA was selected
from each of these 1-mm measurements and was then
compared with the minimum stent lumen CSA chosen by
the visual scanning method to determine the best method
for identifying the minimum IVUS image slice.
A proximal reference site was chosen from the IVUS
images at the lumen cross section 3-mm proximal from the
stent edge. The MLD at this reference site was measured
and was compared with the reference diameter measured by
QCA. Reference measurements were not performed if there
was a major side branch within 3 mm of the proximal stent
edge or if there were two stents placed continuously within
3 mm of each other.
Calculation of expected stent area and diameter. The
manufacturer’s stated balloon diameter at the inflation
pressure written on the package was defined as the expected
stent diameter. Based on this expected diameter, the ex-
pected stent area was calculated as the square of half of the
expected diameter multiplied by . The expected stent
diameter and area were compared with the actual stent
diameter and stent area achieved as assessed by IVUS.
Statistical analysis. All values are expressed as mean 
SD. The paired Student t test was used to compare any two
measurements made on the same patients. Since different
stents within the same patient may not respond indepen-
dently, the patient was chosen as the unit of analysis. The
stent with the largest percent of expected stent area was
chosen for data analysis from each patient who had two or
more stents. Analysis of variance for repeated measures with
a post hoc factorial Bonferroni/Dunn test was used when
more than two measurements were compared. A linear
regression model was used to assess the relationship of stent
lumen CSA between the manufacturer’s expected values and
the in vivo IVUS measurements and between IVUS mea-
surements and QCA measurements for lumen diameter.
The level of significance was set at p 0.05.
RESULTS
Patients characteristics. The mean age of the study pa-
tients was 65  11 years, and 69% were men. Acute
myocardial infarction was the presenting diagnosis in five
cases; six patients had prior myocardial infarction, and four
had prior coronary artery bypass surgery.
Systemic arterial hypertension was present in 19 patients
(59%), diabetes mellitus in 7 (22%), hypercholesterolemia in
26 (81%), and three patients were currently smoking (9%).
Abbreviations and Acronyms
CSA  cross-sectional area
IVUS  intravascular ultrasound
MLD  minimum lumen diameter
QCA  quantitative coronary angiography
Table 1. Angiographic Characteristics
Vessel
LAD 16
LCX 9
RCA 10
LM 1
Vein graft 2
Lesion types*
A 7
B1 6
B2 20
C 5
Quantitative angiography
Reference diameter (mm) 3.0  0.7
Lesion length (mm) 11.5  3.8
MLD (mm)
Baseline 0.7  0.6
Post-stent 3.0  0.6
Percent stenosis (%)
Baseline 76.1  18.1
Post-stent 7.0  6.7
*Modified American Heart Association/American College of Cardiology criteria.
Data are expressed as number of lesions or mean  SD.
LAD  left anterior descending artery; LCX  left circumflex artery; LM  left
main; MLD  minimum lumen diameter; RCA  right coronary artery.
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Angiographic results. Angiographic characteristics are
summarized in Table 1. A total of 38 stents were deployed
in 32 patients. There were 28 de novo lesions. Stent
deployment was successfully completed in all cases, and no
major complication occurred during these procedures. Bal-
loon inflation was performed using 16 atm during stent
deployment in 31 lesions, and 14 atm pressure was used in
seven cases. No lesion received a postdeployment second
dilation before the IVUS examination.
Comparison of two methods for determining the smallest
stent CSA by IVUS. The selection of the image that was
used to measure the minimum stent lumen CSA was
determined by comparing two methods. In 14 lesions from
11 patients, the minimum lumen CSA (5.9  1.4 mm2),
selected by visually scanning the entire IVUS pullback run,
was significantly smaller than the minimum lumen CSA
selected by measuring each 1-mm section of the stent
(6.3  1.5 mm2, p  0.005). However, the MLD was not
significantly different between these two methods (2.5 
0.4 mm, 2.6  0.3 mm, respectively). The difference
between visually scanning the IVUS tape and measuring
frames at 1-mm intervals suggests that the human eye is
capable of picking up the minimal CSA when scanning at
30 frames per second. By measuring a coronary artery
segment at the predetermined 1-mm interval, the smallest
CSA within each 1-mm distance would be overestimated.
Based on the sample observation, the visual scanning
method was used to search for the minimum stent lumen
CSA by IVUS in all cases.
IVUS results. The IVUS imaging was successfully com-
pleted in all stents. As shown in Table 2, the mean stent
MLD was 2.5  0.5 mm, and the mean minimum stent
CSA was 6.0  1.7 mm2.
Comparison of measurements with IVUS and QCA.
The MLD measured by IVUS was significantly smaller than
that measured by QCA both within the stent (2.5 
0.5 mm by IVUS vs. 2.9  0.6 mm by QCA, p  0.0001)
and at the reference site (2.7  0.7 mm by IVUS vs. 3.1 
0.6 mm by QCA, p  0.02). The lumen diameters
measured by IVUS correlated closely with those measured
by QCA but were consistently smaller (y  0.5x  1.7, r 
0.5, p  0.0001).
Comparison of expected stent diameter and area. The
MLD measured either by IVUS (2.5  0.5 mm) or QCA
(3.0  0.4 mm) was significantly smaller than the manu-
facturer’s stated mean balloon diameter (3.5  0.4 mm) at
32 stent sites from 32 patients (Fig. 1). The minimum
lumen CSA measured by IVUS (6.0  1.7 mm2) was also
significantly less compared with the manufacturer’s expected
stent balloon area (calculated based on the balloon diameter
at 9.5  1.9 mm2, p  0.0001) (Fig. 2). There was no
Figure 1. Minimum lumen diameter (MLD) predicted by the manufacturer at the pressure used compared with intravascular ultrasound (IVUS) and
quantitative coronary angiography (QCA) measurements within the stent. The MLD measured by either IVUS or QCA was significantly smaller than the
manufacturer’s expected values.
Table 2. Intravascular Ultrasound Measurements
MLD (mm) 2.5  0.5
% of the manufacturer’s expected stent diameter 72  8
Minimum CSA (mm2) 6.0  1.7
% of the manufacturer’s expected stent area 62  10
Data are expressed as mean  SD.
CSA  cross sectional area; MLD  minimum lumen diameter.
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difference in these results between the two types of stent.
The stent lumen CSA measured by IVUS correlated with
the manufacturer’s expected stent area (r  0.85, p 
0.0001) (Fig. 3). The mean MLD of the stents measured by
IVUS was 72  8% of the expected stent diameter, and the
mean minimum CSA of the stents was 62  10% of the
expected stent area (Table 2, Fig. 4).
Comparison of balloon diameter during inflation with
stent lumen diameter. The maximal balloon diameter
achieved during stent deployment (3.1  0.4 mm) was
significantly smaller than the manufacturer’s expected mean
balloon diameter (p  0.005) but was not significantly
different from the post-stent angiographic MLD measured
by QCA.
Figure 2. Minimum stent lumen cross-sectional area (CSA) predicted by the manufacturer and measured directly by intravascular ultrasound (IVUS). The
measurement of minimum stent CSA by IVUS was significantly smaller than the manufacturer’s expected stent CSA.
Figure 3. Relationship of stent lumen cross-sectional area (CSA) between manufacturer’s stated values and in vivo intravascular ultrasound (IVUS)
measurements. The manufacturer’s expected areas were determined from a combination of two kinds of stents (Guidant/Tristar or AVE-Medtronic/S670),
four stent sizes (2.5 mm, 3.0 mm, 3.5 mm or 4.0 mm) and two inflation pressures (14 or 16 atm).
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DISCUSSION
The new generation of stents have several desirable features
such as easy deliverability, low profile, improved flexibility
and enhanced balloon technology to diminish edge dissec-
tions during stent deployment. In addition, the manufac-
turers are aware that subacute stent thrombosis and resten-
osis are decreased by maximizing the stent lumen CSA. The
balloon composition and deployment characteristics are
developed to ensure that the operator is able to attain the
desired stent lumen diameter. The manufacturers rigorously
test their stent deployment systems and generate a table of
expected stent diameters for a series of inflation pressures.
However, these tests are performed in vitro and in air
without any opposing resistance. Based on our experience
with IVUS measurements of prior stent systems, we hy-
pothesized that the actual stent lumen area achieved might
be less than predicted due to the inherent resistance of
dilating a stent within an atherosclerotic artery. The purpose
of this study was to assess whether the newer stent delivery
systems provide adequate expansion and meet the manufac-
turer’s expected values so that the interventional operator
can reliably depend on the package insert tables.
The manufacturer’s expected stent diameter and area.
The results of this study demonstrate that there is a
significant discrepancy between the manufacturer’s estima-
tion of the stented lumen dimensions and those that are
actually obtained. As measured by IVUS imaging, the
minimum stent lumen CSA was only 62% of the manufac-
turer’s expected stent area. The observed stent MLD was
only 72% of the expected stent diameter. These results were
obtained despite the use of moderately high pressures to
deploy the stents (14 or 16 atm during balloon inflation). If
a lower pressure had been used, such as the recommended
nominal balloon inflation pressure, then a smaller diameter
and CSA would have been achieved (9,13,14). Since a
strong predictor of restenosis is minimum stent lumen CSA,
a smaller than expected lumen would predictably increase
the chance for developing restenosis (15). Based on the
IVUS results, 14 lesions (37%) were redilated with larger
balloons or higher pressures.
Manufacturers provide stent dimensions that are obtained
by balloon inflation in air. The difference between expand-
ing a stent in air versus an artery with resistance might
explain the mismatch between the measured and predicted
stent dimensions. In the seven lesions with the lowest stent
expansion, extensive calcium was present with an arc of 270
to 360°. Four of these seven lesions had rotational atherec-
tomy performed before stenting. The maximum balloon
diameter during stent deployment was not significantly
different from the stented lumen diameter measured by
QCA. This suggests that stent recoil does not play a role in
inadequate stent expansion.
Comparison with previous studies of first generation
stents. The initial observations of coronary artery stenting
with IVUS imaging demonstrated that the recommended
pressures for deployment using the balloons available at that
time resulted in smaller lumen diameters than expected by
the balloon size or the measurements obtained by angio-
graphic QCA (8,10,16). Bermejo et al. (17) reported that
the final acute luminal gain achieved with the first genera-
tion stents (Palmaz-Schatz and Wiktor) at an average of
14 atm inflation pressure was only 55% of the theoretical
value. Because these observations have been generally ac-
cepted by the interventional cardiology community, it has
been assumed that the current state of technology has
advanced such that the balloon size predicted by the
manufacturer’s in vitro testing will be achieved at the time of
actual stent deployment in vivo. This study indicates that
this assumption is incorrect and that a “look up” table is
necessary to interpret the expected stent deployment results
provided by the manufacturers.
The differences in measurements of MLD between IVUS
and QCA. In this study, the MLD measured by IVUS was
significantly smaller than the MLD measured by QCA at
both the in-stent and reference sites. The correlation be-
Figure 4. Stenting a left anterior descending coronary artery lesion. Upper
left panel: Baseline angiogram shows a severe stenosis at the trifurcation of
a diagonal and large septal branch. Upper right panel: After rotational
atherectomy and cutting balloon dilation, a 3.5-mm Tristar stent was
deployed at 16 atm. There is no residual stenosis, but the minimum stent
diameter was 2.8 mm by quantitative coronary angiography. Lower panel:
Intravascular ultrasound (IVUS) imaging just after stenting. Intravascular
ultrasound revealed a major and minor diameter of 3.2 mm by 2.4 mm,
which was 63% of the manufacturer’s expected stent diameter. The
predicted stent area at 16 atm was 11.4 mm2. The actual minimum stent
cross-sectional area measured by IVUS was 6.0 mm2, which was 53% of the
manufacturer’s expected stent area. MLA  minimum lumen area;
MLD  minimum lumen diameter.
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tween these measurements was weak (r  0.5) but consis-
tent with previous studies (18–20). These results may have
been caused by the two measurements not being performed
at exactly the same cross section. In addition, the lumen may
not be circular; thus, the minimal diameter chosen by IVUS
may be less than QCA, even at the same site.
Study limitations. This study is limited because preinter-
vention IVUS imaging was not performed routinely. Thus,
tissue characterization of the underlying atherosclerotic
plaque was not assessed in all lesions. Hard calcified plaque
would be expected to yield less expansion than softer plaque.
However, if plaque characterization were taken into ac-
count, it is likely that the manufacturer’s expected stent area
and diameter would be even less when calcified plaque is
present. In addition, in patients who received directional
atherectomy, the resistance to stent expansion might be
reduced due to removal of plaque bulk. However, this series
of patients was nonselected by lesion type and is represen-
tative of our patient population.
Conclusions. Despite moderately high inflation pressure,
the mean minimum stent CSA was only 62% of the
manufacturer’s expected stent area. To optimize stent de-
ployment, even with the newer generation of flexible,
low-profile stents, these IVUS observations should be con-
sidered during coronary artery stenting, especially if lower
pressures are used during deployment.
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